Janssen Research & Development LLC (JRD) - Articles and news items

Clinical remission data for Stelara in Crohn’s disease presented at DDW

Industry news / 25 May 2016 / Victoria White, Digital Content Producer

Data shows that a greater proportion of adult patients with Crohn’s disease receiving Stelara SC maintenance therapy were in clinical remission at one year…

Stelara induces clinical remission in Crohn’s disease in Phase 3 trial

Industry news / 20 October 2015 / Victoria White

The Phase 3 study achieved its primary endpoint with Stelara treatment groups demonstrating significantly higher rates of clinical response at week 6…

Johnson & Johnson and collaborators launch the Open Translational Science Project in Schizophrenia

Industry news / 9 June 2015 / Victoria White

Johnson & Johnson and a group of leading research organisations are launching the OPTICS Project – Open Translational Science in Schizophrenia…

Janssen Pharmaceuticals Logo

U.S. FDA grants Priority Review to simeprevir for combination treatment of genotype 1 chronic hepatitis C

Industry news, News / 13 May 2013 / Johnson & Johnson

The U.S. FDA has granted Priority Review to the NDA for simeprevir (TMC435)…

Janssen-Cilag International NV Logo

New Phase 3 data show STELARA® significantly reduced signs and symptoms of active Psoriatic Arthritis

Industry news / 27 June 2012 / Janssen Research & Development, LLC

Treatment also resulted in significant improvements in physical function…

Janssen Pharmaceuticals Logo

Janssen Research & Development submits application to U.S. FDA for XARELTO® (rivaroxaban) to reduce secondary cardiovascular events in patients with ACS

Industry news, News / 29 December 2011 / Janssen Research & Development, LLC

Janssen Research & Development, LLC (JRD) have announced that it has submitted a sNDA to the FDA seeking approval for the use of XARELTO® (rivaroxaban)…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...